Current knowledge and future prospects on the treatment of multidrug-resistant tuberculosis with second-line injectable agents

doi:10.3969/j.issn.1000-6621.2019.06.004

Abstract

Abstract:

WHO Treatment guidelines for multidrug- and rifampicin-resistant tuberculosis (2018 update) was issued in late 2018 to improve MDR/RR-TB care, in which a new all-oral 20-month treatment regimen is now proposed, prioritising oral drugs over injectables. A shorter MDR-TB regimen of 9-12 months was recommended to use instead of the longer regimens under some specific circunstances, including the daily use of second-line injec-table agents for at least 4 months. Under the background, we review the drug resistance mechanism, clinical effectiveness, adverse reaction and role change of second-line injectable agents commonly used in the treatment of MDR-TB in China and address the rational use of second line injection.

Key words: Antitubercular agents, Injections, Amikacin, Capreomycin, Tuberculosis, multidrug-resistant, Regimens evaluation

Guo-fang DENG,Pei-ze ZHANG,Min YANG,Liang FU. Current knowledge and future prospects on the treatment of multidrug-resistant tuberculosis with second-line injectable agents[J]. Chinese Journal of Antituberculosis, 2019, 41(6): 604-608. doi: 10.3969/j.issn.1000-6621.2019.06.004

References 35

[1]	World Health Organization , Health statistics and information systems. Disease burden and mortality estimates-child causes of death,2000—2017. Geneva: World Health Organization, 2018.
[2]	World Health Organization . World tuberculosis report 2018. Geneva: World Health Organization, 2018.
[3]	World Health Organization . Treatment guidelines for multidrug- and rifampicin-resistant tuberculosis 2018 update. Geneva: World Health Organization, 2019.
[4]	张文宏, 孙峰, 李杨 . 世界卫生组织新短程耐多药结核病化学治疗方案: 适逢其时还是太过仓促. 中华传染病杂志, 2017,35(12):711-714.
[5]	World Health Organization . Guidelines for the programmatic management of drug-resistant tuberculosis:Emergency update 2008. Geneva: World Health Organization, 2008.
[6]	中国防痨协会. 耐药结核病化学治疗指南(2015). 中国防痨杂志, 2015,37(5):421-469.
[7]	Caminero JA . Treatment of multidrug-resistant tuberculosis: evidence and controversies. Int J Tuberc Lung Dis, 2006,10(8):829-837.
[8]	World Health Organization . Guidelines for the programmatic management of drug-resistant tuberculosis, 2011 update. Geneva: World Health Organization, 2011.
[9]	World Health Organization . 2014 companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. Geneva: World Health Organization, 2014.
[10]	World Health Organization . World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update. Geneva: World Health Organization, 2016.
[11]	中华医学会. 临床诊疗指南: 结核病分册. 北京: 人民卫生出版社, 2005.
[12]	Sotgiu G, Tiberi S, D’Ambrosio L, , et al. WHO recommendations on shorter treatment of multidrug-resistant tuberculosis. Lancet, 2016,387(10037):2486-2487. doi: 10.1016/S0140-6736(16)30729-2 URL
[13]	Davis A, Meintjes G, Wilkinson RJ . Treatment of tuberculous meningitis and its complications in adults. Curr Treat Options Neurol, 2018,20(3):5. doi: 10.1007/s11940-018-0490-9
[14]	刘雪梅, 谢建平 . 卷曲霉素作用机制和耐药机制的功能基因组学研究进展. 药学学报, 2008,43(8):788-792.
[15]	全国第五次结核病流行病学抽样调查技术指导组, 全国第五次结核病流行病学抽样调查办公室. 2010年全国第五次结核病流行病学抽样调查报告. 中国防痨杂志, 2012,34(8):485-508.
[16]	Zhang Z, Liu M, Wang Y , et al. Molecular and phenotypic characterization of multidrug-resistant Mycobacterium tuberculosis isolates resistant to kanamycin, amikacin, and capreomycin in China. Eur J Clin Microbiol Infect Dis, 2014,33(11):1959-1966. doi: 10.1007/s10096-014-2144-5 URL
[17]	宋艳华, 付育红, 陆宇 , 等. 结核分枝杆菌对4种注射用抗结核药耐药情况分析. 中国临床医生杂志, 2013,41(3):36-39.
[18]	常珊, 付育红, 李琦 , 等. 结核分枝杆菌临床分离株对四种注射用抗结核药物耐药及交叉耐药分析. 中国防痨杂志, 2013,35(1):37-40.
[19]	Nasiri MJ, Haeili M, Ghazi M , et al. New insights in to the intrinsic and acquired drug resistance mechanisms in mycobacteria. Front Microbiol, 2017,8:681. doi: 10.3389/fmicb.2017.00681 URL
[20]	Kempker RR, Kipiani M, Mirtskhulava V , et al. Acquired drug resistance in Mycobacterium tuberculosis and poor outcomes among patients with multidrug-resistant tuberculosis. Emerg Infect Dis, 2015,21(6):992-1001. doi: 10.3201/eid2106.141873 URL
[21]	Smith SE, Ershova J, Vlasova N , et al. Risk factors for acquisition of drug resistance during multidrug-resistant tuberculosis treatment, Arkhangelsk Oblast, Russia, 2005—2010. Emerg Infect Dis, 2015,21(6):1002-1011. doi: 10.3201/eid2106.141907 URL
[22]	Brossier F, Pham A, Bernard C , et al. Molecular investigation of resistance to second-line injectable drugs in multidrug-resistant clinical isolates of Mycobacterium tuberculosis in France. Antimicrob Agents Chemother, 2017, 61(2). pii:e01299-16.
[23]	Ahmad N, Ahuja SD, Akkerman OW , et al. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet, 2018,392(10150):821-834. doi: 10.1016/S0140-6736(18)31644-1 URL
[24]	Shin S, Furin J, Alcantara F , et al. Hypokalemia among patients receiving treatment for multidrug-resistant tuberculosis. Chest, 2004,125(3):974-980. doi: 10.1378/chest.125.3.974 URL
[25]	Seddon JA, Thee S, Jacobs K , et al. Hearing loss in children treated for multidrug-resistant tuberculosis. J Infect, 2013,66(4):320-329. doi: 10.1016/j.jinf.2012.09.002 URL
[26]	Arnold A, Cooke GS, Kon OM , et al. Adverse effects and choice between the injectable agents amikacin and capreomycin in multidrug-resistant tuberculosis. Antimicrob Agents Chemother, 2017, 61(9). pii:e02586-16.
[27]	Ahuja SD, Ashkin D, Avendano M , et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9153 patients. PLoS Med, 2012,9(8):e1001300. doi: 10.1371/journal.pmed.1001300 URL
[28]	Harausz EP, Garcia-Prats AJ, Law S , et al. Treatment and outcomes in children with multidrug-resistant tuberculosis: A systematic review and individual patient data meta-analysis. PLoS Med, 2018,15(7):e1002591. doi: 10.1371/journal.pmed.1002591 URL
[29]	Van Deun A, Maug AK, Salim MA , et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med, 2010,182(5):684-692. doi: 10.1164/rccm.201001-0077OC URL
[30]	中华医学会结核病学分会, 耐多药结核病短程治疗中国专家共识编写组. 耐多药结核病短程治疗中国专家共识. 中华结核和呼吸杂志, 2019,42(1):5-8.
[31]	Sotgiu G, Migliori GB . Effect of the short-course regimen on the global epidemic of multidrug-resistant tuberculosis. Lancet Respir Med, 2017,5(3):159-161. doi: 10.1016/S2213-2600(16)30432-5 URL
[32]	Campbell JR, Menzies D . What’s next for the standard short-course regimen for treatment of multidrug-resistant tuberculosis. Am J Trop Med Hyg, 2019,100(2):229-230. doi: 10.4269/ajtmh.18-0985 URL
[33]	Walsh KF, Souroutzidis A, Vilbrun SC , et al. Potentially high number of ineffective drugs with the standard shorter course regimen for multidrug-resistant tuberculosis treatment in Haiti. Am J Trop Med Hyg, 2019,100(2):392-398. doi: 10.4269/ajtmh.18-0493 URL
[34]	Dharmadhikari AS, Kabadi M, Gerety B , et al. Phase I, single-dose, dose-escalating study of inhaled dry powder capreomycin: a new approach to therapy of drug-resistant tuberculosis. Antimicrob Agents Chemother, 2013,57(6):2613-2619. doi: 10.1128/AAC.02346-12 URL
[35]	Schoubben A, Giovagnoli S, Tiralti MC , et al. Capreomycin inhalable powders prepared with an innovative spray-drying technique. Int J Pharm, 2014,469(1):132-139. doi: 10.1016/j.ijpharm.2014.04.042 URL